Exact Sciences has acquired a worldwide exclusive license for targeted digital sequencing (TARDIS) technology from the Translational Genomics Research Institute.
TARDIS is able to detect trace amounts of tumor DNA in patients' blood up to 100 times better than conventional technology, the firm said.
